COVID-19-Driven Immunoparalysis and Cytokine Storm: Can Hematologists Contribute to the Battle?
Journal: Haematology International Journal (HIJ) (Vol.4, No. 2)Publication Date: 2020-07-03
Authors : Marchetti M;
Page : 1-12
Keywords : COVID-19; SARS-CoV; Lymphopenia; IL-6; GM-CSF; Tocilizumab; Baricitinib; Ruxolitinib; Siltuximab; Sarilumab;
Abstract
COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high reported morbidity has been related to derangement of the immune system, cytokine overproduction and endothelial dysfunction. Several drugs currently marketed for blood disorders are being tested for potential clinical benefit in patients with COVID-19 and hematologists are valuable partners for multidisciplinary research projects assessing host-targeted therapies. This review attempts to highlight the pathogenesis of lymphopenia in COVID-19 disease and the possible treatment pathways. While discussing the pattern of cytokine hyperproduction, we also focused on anti-cytokine drugs being tested for COVID-19 disease but currently prescribed for blood disorders
Other Latest Articles
- Diversity of Clinical Features of Patients with Thalassemia Intermedia
- IMPACT OF NOTCH GEOMETRY ON THE FATIGUE LIFE OF BS 970-4 GRADE 349S52 STAINLESS STEEL
- Determining Transfusion Needs: Expectations and Realities?
- Sickle Cell Disease Control Prospects the Emerging Necessities Due to Impactful COVID-19 Pandemic in Sub Saharan Africa
- Thrombocytosis on Adult Patient with SARS-Cov-2 in Africa
Last modified: 2022-09-12 18:19:01